{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=chemotherapy&page=2", "query": { "intervention": "chemotherapy", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=chemotherapy&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-25T16:39:31.523Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04345952", "title": "Calm for Cancer Patients Receiving Chemotherapy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer Colorectal" ], "interventions": [ { "name": "Calm Meditation Mobile App", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-02", "completion_date": "2023-12", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-09-25T16:39:31.523Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04345952" }, { "nct_id": "NCT05712278", "title": "A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukaemia" ], "interventions": [ { "name": "SAR445419", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2023-06-16", "completion_date": "2024-03-12", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-09-25T16:39:31.523Z", "location_count": 3, "location_summary": "Omaha, Nebraska • The Bronx, New York • Houston, Texas", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "The Bronx", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05712278" }, { "nct_id": "NCT05353985", "title": "A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Celiac Disease" ], "interventions": [ { "name": "TAK-062", "type": "DRUG" }, { "name": "Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar", "type": "DIETARY_SUPPLEMENT" }, { "name": "TAK-062 Placebo", "type": "DRUG" }, { "name": "Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 153, "start_date": "2022-06-30", "completion_date": "2024-11-06", "has_results": true, "last_update_posted_date": "2025-08-20", "last_synced_at": "2026-09-25T16:39:31.523Z", "location_count": 61, "location_summary": "Birmingham, Alabama • Litchfield Park, Arizona • Paradise Valley, Arizona + 52 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Litchfield Park", "state": "Arizona" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05353985" }, { "nct_id": "NCT04437485", "title": "eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Depression", "Major Depressive Disorder", "Dysthymic Disorder", "Depressive Symptoms", "Type 2 Diabetes", "PreDiabetes", "Insulin Resistance" ], "interventions": [ { "name": "Good Days Ahead (GDA)", "type": "BEHAVIORAL" }, { "name": "Problem Solving Treatment in Primary Care (PST-PC)", "type": "BEHAVIORAL" }, { "name": "Antidepressant Medications", "type": "DRUG" }, { "name": "Active Control", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "DRUG", "OTHER" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2020-10-14", "completion_date": "2022-08-29", "has_results": true, "last_update_posted_date": "2023-11-02", "last_synced_at": "2026-09-25T16:39:31.523Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04437485" }, { "nct_id": "NCT03602235", "title": "High Dose Ascorbic Acid for Plasma Cell Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Ascorbate", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Christopher Strouse", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2019-03-05", "completion_date": "2025-09-03", "has_results": false, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-09-25T16:39:31.523Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT03602235" }, { "nct_id": "NCT01941316", "title": "Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Carcinoma", "Non Small Cell Lung Carcinoma", "Irinotecan Sensitive Cancers" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cancer Research and Biostatistics Clinical Trials Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2013-11", "completion_date": "2019-07-01", "has_results": true, "last_update_posted_date": "2024-05-09", "last_synced_at": "2026-09-25T16:39:31.523Z", "location_count": 8, "location_summary": "Goodyear, Arizona • Lexington, Kentucky • Louisville, Kentucky + 5 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01941316" }, { "nct_id": "NCT04266249", "title": "CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Invasive Breast Carcinoma", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Lumpectomy", "type": "PROCEDURE" }, { "name": "Mastectomy", "type": "PROCEDURE" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL", "RADIATION" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2175, "start_date": "2020-03-13", "completion_date": "2038-12-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-25T16:39:31.523Z", "location_count": 999, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 674 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04266249" }, { "nct_id": "NCT00002955", "title": "Combination Chemotherapy in Treating Patients With Advanced Cancer of the Pancreas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "trimetrexate glucuronate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "1995-08", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2014-05-22", "last_synced_at": "2026-09-25T16:39:31.523Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002955" }, { "nct_id": "NCT02723955", "title": "Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "feladilimab (GSK3359609)", "type": "DRUG" }, { "name": "GSK3174998", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel plus Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine plus Carboplatin", "type": "DRUG" }, { "name": "Fluorouracil (5-FU) plus carboplatin or cisplatin", "type": "DRUG" }, { "name": "Dostarlimab", "type": "DRUG" }, { "name": "Cobolimab", "type": "DRUG" }, { "name": "Bintrafusp alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "93 Years", "sex": "ALL", "summary": "18 Years to 93 Years" }, "enrollment_count": 829, "start_date": "2016-06-23", "completion_date": "2023-07-05", "has_results": true, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-09-25T16:39:31.523Z", "location_count": 9, "location_summary": "Duarte, California • Los Angeles, California • Sarasota, Florida + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02723955" }, { "nct_id": "NCT00335998", "title": "Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Cervical Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Vaginal Cancer", "Recurrent Vulvar Cancer", "Stage III Vaginal Cancer", "Stage IIIA Cervical Cancer", "Stage IIIA Ovarian Epithelial Cancer", "Stage IIIA Vulvar Cancer", "Stage IIIB Cervical Cancer", "Stage IIIB Ovarian Epithelial Cancer", "Stage IIIB Vulvar Cancer", "Stage IIIC Ovarian Epithelial Cancer", "Stage IIIC Vulvar Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IVA Cervical Cancer", "Stage IVA Vaginal Cancer", "Stage IVB Cervical Cancer", "Stage IVB Vaginal Cancer" ], "interventions": [ { "name": "triapine", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "external beam radiation therapy", "type": "RADIATION" }, { "name": "brachytherapy", "type": "RADIATION" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2006-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-11", "last_synced_at": "2026-09-25T16:39:31.523Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00335998" } ] }